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1.1. 2-Arylbenzoxazoles as new cholesteryl ester transfer
protein inhibitors
The treatment of coronary heart disease utilising a lipid
modifying modality has focused on lowering circulating
levels of low-density lipoprotein cholesterol (LDL-C). In
turn, drug discovery eﬀorts have focused on investigating
mechanisms that have the potential for raising high-density
lipoprotein cholesterol (HDL-C) in plasma in the belief
that there is an inverse relationship between HDL-C levels
and the risk of coronary heart disease. Current therapies
such as ﬁbrates or niacin exert only a moderate eﬀect on
increasing HDL-C levels while displaying signiﬁcant side
eﬀects.
Thus there remains a need for a safer and more eﬃcacious
method of increasing HDL-C levels. In this regard, cho-
lesteryl ester transfer protein (CETP), which is a 74-kDa
plasma glycoprotein secreted by the liver, has been investi-
gated. CETP facilitates the transfer of the cholesterol ester
from HDL to LDL and VLDL in exchange for triglycer-
ides and furthermore, CETP inhibition leads to increased
HDL-C in humans. HDL particles can accept cholesterol
from peripheral tissues such as macrophages, and thus
CETP inhibitors could promote reverse cholesterol trans-
port and therefore be anti-atherogenic.
Recent work has led to the identiﬁcation and optimisation
of a novel series of 2-arylbenzoxazole-based CETP inhibi-
tors.1 This publication describes a screening campaign, car-
ried out using a ﬂuorescence assay, and potent compounds
discovered were evaluated for activity in a human whole
plasma assay (WPA). A 2-arylbenzoxazole hit (1), with
an IC50 value of 10 lM in the WPA assay, was obtained
as a starting point for further investigation. The modular
structure of this chemotype was well suited for rapid explo-doi:10.1016/j.comche.2008.06.001
E-mail: nterrett@ensemblediscovery.comration of its SAR through the application of parallel
synthesis.
The strategy involved developing chemistry that allowed
exploration of substitutions on either the fused phenyl of
the benzoxazole (A) or the phenyl ether (B), marked on
1. The synthetic strategy to study various A ring substitu-
tions involved the formation of two amide bonds to deliver
compounds of generic structure 2 which then underwent a
microwave assisted acid-promoted cyclisation of the ani-
lide-alcohol (2) using p-toluenesulphonic acid to deliver
compounds of general structure 3. The average purity (by
HPLC-UV) of the ﬁnal products was 94%.
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The synthetic approach used to vary the B-ring proceeded
via formation of an aniline (4) and then exploration of the
B-ring through the parallel synthesis of aryloxyacetyl chlo-
rides, to provide the desired products of generic structure 5.
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sity contained within ﬁnal compounds, the aniline (4) was
acylated with chloroacetyl chloride to give 6. This com-
pound then underwent a displacement of chlorine with
phenols using parallel synthesis to give the desired products
with generic structure 5 with an average purity of 98%, as
determined by HPLC-UV. From these libraries, several
compounds were obtained that displayed reasonable activ-
ity: one of the most potent tested was 7 which revealed an
IC50 of 0.91 lM in the WPA assay.
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1.2. 1,4-Dihydroindeno[1,2-c]pyrazoles as potent and selec-
tive checkpoint kinase 1 inhibitors
A stratagem used in the battle against cancer is the applica-
tion of treatments that cause selective DNA damage. The
eﬀectiveness of these cytotoxic treatments, such as ionising
UV radiation and chemotherapy, is compromised by severe
side eﬀects and drug resistance. A solution to these prob-
lems may lie in sensitisation of DNA-damaging treatments
to make them more potent and/or more selective toward
tumour cells.
Recently, there have been studies on the role of checkpoint
kinase 1 (CHK-1) in the cell cycle as a response to geno-
toxic stresses. These studies demonstrated that inhibition
of CHK-1 oﬀers a mechanism for sensitising various
DNA-damaging therapies. Human CHK-1 is a serine/thre-
onine kinase that is phosphorylated by the upstream ki-
nases ATR and/or ATM following DNA damage. CHK-
1 subsequently phosphorylates Cdc25A and induces its
degradation. This results in inhibition of the downstreamcyclin E/Cdk2 or cyclin B/Cdc2 kinases, leading to cell cy-
cle arrest at the S phase or G2/M phase, respectively. As
tumour cells can arrest at diﬀerent cell cycle checkpoints
mediated by CHK-1, they have a chance to repair them-
selves. Thus, inhibition of CHK-1 to remove S and G2/
M checkpoints will cause tumour cells to undergo prema-
ture mitotic entry, leading to cell death.
Tumour cells and normal cells diﬀer in that tumour cells
are often deﬁcient in p53, preventing arrest at the G1
checkpoint, whereas, in response to DNA damage, normal
cells are capable of arresting at G1 checkpoint through the
p53-mediated pathway, ensuring genomic integrity. This
diﬀerence provides the potential for a therapeutic window
for sensitising DNA-damaging treatments of cancer using
CHK-1 inhibitors. A recent publication reports the discov-
ery of 1,4-dihydroindeno[1,2-c]pyrazoles as a new class of
CHK-1 kinase inhibitors.2
The program used the screening hit 8 as a starting point for
further design. This compound possessed an IC50 of 510
nM against CHK-1. An x-ray co-crystal structure of 8
bound to the CHK-1 active site indicated to the project
team that they should focus their eﬀorts on elucidating
SAR around the ﬂuoro group because it occupied a region
where extra hydrogen bonding between the inhibitor and
several polar residues of the backbone protein could be
envisioned. A hit-to-lead process was then undertaken sup-
ported by x-ray crystallography. From these rounds of
medicinal design, a number of potent compounds were ob-
tained that possessed inhibitory properties against CHK-1.
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One of the most potent compounds was 9 which possessed
an IC50 value of 6.2 nM. Compounds active in the enzy-
matic inhibition assay, such as 9, were then tested in two
cellular assays. A cell proliferation assay (MTS assay) in
HeLa cells (a human cervical cancer cell line) was used to
measure the ability of CHK-1 inhibitors to sensitise cells
to the DNA-damaging agent, doxorubicin. An EC50 was
determined for the inhibitor as a single agent and the inhib-
itor in combination with doxorubicin; with the ratio being
a relative scale of an inhibitor’s ability to potentiate the
DNA-damaging agent. Additionally, a cell cycle analysis
(FACS assay) in H1299 cells (a human lung cancer cell line)
was performed to determine if the mechanism of doxorubi-
cin sensitisation is through abrogation of G2/M check-
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CHK-1 inhibitor that reduces doxorubicin-induced G2/M
cell population by half, or it was measured in the absence
of doxorubicin. Compound 9 possessed an EC50 of 1.8
lM in the MTS assay, and an EC50 of 770 nM in the FACS
assay (with doxorubicin present).2. A summary of the papers in this month’s issue
2.1. Solid-phase synthesis
Chemical stability and reactivity of a bifunctional polymer
conjugate containing an ortho-amino arylamide linkage
have been successfully exploited to achieve a parallel syn-
thesis of methoxycarbonylated head–tail bis-benzimidaz-
oles. Regioselective alkylation of the two nitrogens in the
benzimidazolone moiety has been carried out by ipso-ﬂu-
oro displacement, and N-alkylation to generate two diver-
sities, and cleavage of the polymer support has resulted in
two libraries of di-and tri-substituted benzimidazolyl ben-
zimidazolones in high purity and high yield.3
The solid-phase synthesis of several 5-aminoimidazole-4-
(N-alkyl)carboxamide-1-ribosides (4-N-alkyl AICARs)
and the corresponding 20,30-secoriboside derivatives has
been reported. The method uses N-1-dinitrophenyl-inosine
50-bound to a solid support, and has the C-2 of the purine
base strongly activated towards attack of N-nucleophiles.
This allows preparation of several N-1 alkylated inosine
supports from which a small library of 4-N-alkyl AICAR
derivatives has been synthesised.4
A collection of 131 small molecules, reminiscent of families
of long chain N-acyl tyrosines, enamides and enol esters
that have been isolated from heterologous expression of
environmental DNA (eDNA) in Escherichia coli, has been
prepared. The synthetic libraries of N-acyl tyrosines and
their 3-keto counterparts were prepared via solid-phase
routes, whereas the enamides and enol esters were synthe-
sised in solution-phase.5
2.2. Solution-phase synthesis
No papers this month.
2.3. Scaﬀolds for combinatorial libraries
A positional scanning synthetic combinatorial library has
been employed to determine the conformation of bicyclic
guanidines with kappa-opioid receptor activity. A common
bioactive conformation and putative pharmacophoric fea-
tures have been suggested by means of 3D similarity meth-
ods. Comparison of this model with known opiates
suggests a similar binding mode showing that the bicyclic
guanidines presented in this work are suitable scaﬀolds
for further development of new opioid receptors ligands.6
2.4. Solid-phase supported reagents
A wide range of commercial diazodicarboxylates and phos-
phines have been screened in an attempt to ﬁnd puriﬁca-tion-free conditions for application in parallel synthesis.
The combination of immobilised triphenylphosphine and
TMAD proved to be suitable for the synthesis of aryl
ethers via the Mitsunobu reaction, and nine ethers were
synthesised in good yield and excellent purity.7
Three polymer-supported quaternary ammonium mesy-
lates have been synthesised for use as recyclable polymeric
phase transfer catalysts (PTCs). Through a comparative
study using nucleophilic ﬂuorination, one tertiary alco-
hol-containing polymer proved to be the best catalyst with
high activity and chemoselectivity.8
A facile method for the enantioseparation of functionalised
Tro¨ger’s base analogues possessing various substitution
patterns has been developed. The systematic separation
of a library comprising 36 representatives on a commer-
cially available chiral stationary phase provided valuable
information on structure–enantioselectivity relationships.9
A one-pot, two-step protocol for the microwave-assisted
solid-phase synthesis of substituted benzoxazoles has been
developed. This approach starts from diﬀerent polymer-
bound esters previously designed as solid-supported re-
agents for the acylation of amines, alcohols and phenols.
The combination of a parallel synthesiser and a microwave
reactor allowed rapid preparation of a collection of
substituted benzoxazoles in high purity and satisfactory
yields.10
2.5. Novel resins, linkers and techniques
l,6-Dioxaspiro[4,4]nonane-2,7-dione has been found to
react readily with alcohols in the presence of 1,8-diazabi-
cyclo[5,4,0]undec-7-ene (DBU). The 4-oxoheptanedioic
acid tether obtained bears a free carboxy group, which
enables anchoring to aminoalkylated resins. There is also
a 4-oxobutanoate structural motif, which allows release
of the target alcohol by a mild hydrazinium acetate treat-
ment. Nucleosides have been derivatised with this simple
difunctional linker arm, anchored to a solid phase and
subjected to synthesis and subsequent release of oligonu-
cleotides bearing base-sensitive biodegradable phosphate
protection.11
Peptides are limited in their use as drugs due to low cell
permeability and vulnerability to proteases. In contrast,
peptoids are immune to enzymatic degradation and some
peptoids have been shown to be relatively cell permeable.
In order to facilitate future design of peptoid libraries for
screening experiments, the strengths and limitations of a
high-throughput cell-based permeability assay that regis-
ters the relative ability of steroid-conjugated peptides and
peptoids to enter a cell have been assessed.12
2.6. Library applications
A heteroaromatic 6,7-diaryl-2,3,8,8a-tetrahydroindolizin-
5(1H)-one library has been prepared and tested for cyto-
toxic properties against the HCT-116 colon cancer cell line,
thus providing information pertaining to structure–activity
relationships for this class of compounds.13
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tual screening and synthesis of a small library has been per-
formed to identify hits for the potential antimycobacterial
drug target, glutamine synthetase. Based on one of the hits
from virtual screening, a small library of 15 analogues was
synthesised producing four compounds that inhibited glu-
tamine synthetase.14
The related 3C and 3C-like proteinase (3Cpro and 3CLpro)
of picornaviruses and coronaviruses, respectively, are good
drug targets. As part of an eﬀort to generate broad-spec-
trum inhibitors of these enzymes, a library of inhibitors
based on a halopyridinyl ester was prepared. Three of the
compounds inhibited the cleavage activity of HAV 3Cpro
with Kics of 120–240 nM - among the most potent non-pep-
tidic inhibitors reported to date against a 3Cpro.15
Vancomycin is mainly used as an antibacterial agent of last
resort, but recently vancomycin-resistant bacterial strains
have been emerging. A recent study aimed to create new
anti-drug-resistance antibacterials which can be synthesised
in a few steps from inexpensive starting materials. Sulpha
derivatives that inhibit dihydropteroate synthase (DHPS)
in the folate pathway would act as folate metabolite-mim-
ics and inhibit bacterial folate metabolism. Screening of
sulphonanilide libraries led to the discovery of benzene-
sulphonanilides with potent anti-methicillin-resistant
Staphylococcus aureus (MRSA)/vancomycin-resistant
Enterococcus (VRE) activity.16
Synthesis and in vitro evaluation of a library of modiﬁed
endomorphin 1 peptides has been prepared. The N- and
C-termini of Endo-1 were modiﬁed by lipoamino acids
(Laa) and/or sugars to overcome metabolic instability
and poor membrane permeability. Analogues were assessed
for l-opioid receptor aﬃnity, inhibition of cAMP accumu-
lation, enzymatic stability, and permeability across Caco-2
cell monolayers.17
An immobilised Staurosporine aglycone isostere, where
one of the indole nitrogen atoms was replaced by carbon,
has been sequentially functionalised to generate com-
pounds that inhibit TrkA kinase. In the ﬁrst phase, initial
screening of a library of C13-hydroxymethyl-7-oxo-inden-
opyrrolocarbazoles resulted in several potent compounds,
one of which was further optimised to generate the corre-
sponding carbamates on solid phase.18
Insulin-like growth factor receptor (IGF-1R) is a growth
factor receptor tyrosine kinase that acts as a critical medi-
ator of cell proliferation and survival. This receptor is over-
expressed or activated in tumour cells and is emerging as a
novel target in cancer therapy. A novel series of submi-
cromolar IGF-1R inhibitors based on an isoquinolinedione
template has been reported. Chemical triage and parallel
synthesis incorporating focused library arrays were instru-
mental in moving this discovery forward.19
Synthesis, biological evaluation, and SAR dependencies
for a library of novel aryl and heteroaryl substituted N-
[3-(4-phenylpiperazin-1-yl)propyl]-1,2,4-oxadiazole-5-carb-
oxamide inhibitors of GSK-3b kinase have been described.The inhibitory activity of the synthesised compounds is
highly dependent on the character of substituents in the
phenyl ring and the nature of terminal heterocyclic frag-
ment of the core molecular scaﬀold.20
The molecular duplication of non-nucleoside reverse
transcriptase inhibitor (NNRTI) O-(2-phthalimidoethyl)–
N-arylthiocarbamates has led to the identiﬁcation of
symmetric formimidoester disulphides as a novel class of
potent NNRTIs. The lead compound prevented wild-type
HIV-1 multiplication in MT-4 cell culture with an EC50
value of 0.35 lM. To perform a structure–activity relation-
ship study, 40 analogues of the lead compound were
prepared by an unprecedented one-pot method of solu-
tion-phase parallel synthesis.21
The cyclodepsipeptide Jaspamide is an interesting marine
metabolite, that possesses a potent inhibitory activity
against breast and prostate cancer, as a consequence of
its ability to disrupt actin cytoskeleton dynamics. A recent
report describes the synthetic modiﬁcation of the natural
metabolite, generating small arrays of unnatural variants.22References
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